A Study of LY3041658 in Participants With Skin Diseases

Lilly

Status and phase: Completed; Phase 1

Conditions: Psoriasis; Skin Diseases

Treatments: Drug: LY3041658; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT02896868

15165

I7P-MC-DSAB (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to investigate the safety and tolerability of the study drug known as LY3041658 in participants with certain types of skin diseases. The study will measure how the body absorbs, breaks down and gets rid of LY3041658. It will last about 127 days for each participant, not including screening. This study is for research purposes only, and is not intended to treat any medical condition.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Investigator confirmed diagnosis of certain skin diseases for at least 6 months.
• Active skin lesions that are not responding to standard therapies.
• Willing to undergo pre- and post-treatment skin biopsies of lesions.

Exclusion criteria

• Have other skin diseases that may interfere with evaluation of the specified skin disease being studied.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind

---

60 participants in 2 patient groups, including a placebo group

LY3041658

Experimental group

Description:

LY3041658 administered intravenously (IV) once every two weeks over 6 weeks (four doses).

Treatment:

Drug: LY3041658

Placebo

Placebo Comparator group

Description:

Placebo administered IV once every two weeks over 6 weeks (four doses).

Treatment:

Drug: Placebo